Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 1
2022 5
2023 4
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Characteristics and clinical outcomes of Japanese patients with venous thromboembolism receiving under-dose rivaroxaban: subanalysis of J'xactly.
Fukamachi D, Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Mo M, Yamazaki T, Hirayama A; J’xactly Investigators. Fukamachi D, et al. Curr Med Res Opin. 2022 Jul;38(7):1059-1068. doi: 10.1080/03007995.2022.2070379. Epub 2022 May 6. Curr Med Res Opin. 2022. PMID: 35502571
Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism　- Insights From the J'xactly Study.
Yamashita T, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Ikeda T, Mo M, Yamazaki T, Okumura Y, Hirayama A; J’xactly Investigators. Yamashita T, et al. Circ Rep. 2022 Jul 13;4(8):371-377. doi: 10.1253/circrep.CR-22-0011. eCollection 2022 Aug 10. Circ Rep. 2022. PMID: 36032386 Free PMC article.
CORRIGENDUM: A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).
Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Mo M, Kobayashi T, Niwa A, Matsuo H, Yokoi H, Koga M, Yamazaki T, Hirayama A; J’xactly Investigators. Okumura Y, et al. Circ J. 2021;85(3):330. doi: 10.1253/circj.CJ-66-0190. Circ J. 2021. PMID: 33627587 Free article. No abstract available.
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Mo M, Yamazaki T, Hirayama A; J’xactly Investigators. Okumura Y, et al. BMJ Open. 2018 Jun 22;8(6):e020286. doi: 10.1136/bmjopen-2017-020286. BMJ Open. 2018. PMID: 29934383 Free PMC article.
A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).
Okumura Y, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Mo M, Kobayashi T, Niwa A, Matsuo H, Yokoi H, Koga M, Yamazaki T, Hirayama A; J’xactly Investigators. Okumura Y, et al. Circ J. 2020 Oct 23;84(11):1912-1921. doi: 10.1253/circj.CJ-20-0636. Epub 2020 Sep 26. Circ J. 2020. PMID: 32981924 Free article.